Skip to main content

Editors' Pick: SARS-CoV-2 COVID-19 Susceptibility and Lung Inflammatory Storms by Smoking and Vaping

Aging, smoking/vaping results in severe disease outcome and mortality amongst COVID-19 patients. SARS-CoV-2 with a membrane spike glycoprotein furin along with its receptor ACE2 and TMPRSS2 protease are increased by smoking/vaping in lung epithelium rendering viral entry and augmented infection. This results in a ‘cytokine storm’ involving excessive production of pro-inflammatory cytokines/chemokines. This review therefore discusses the impact of smoking /vaping on the key inflammatory mechanisms following Covid-19 infection and the possible therapeutic strategies required to overcome this excessive inflammatory response.

From theory to therapy; understanding and targeting immunometabolism for the treatment of inflammation and cancer

Edited by:
Dr. Peter Bunyard, Ph.D., Sitryx Therapeutics, United Kingdom
Dr. pharm. Marina Makrecka-Kuka, Ph.D., Sitryx Therapeutics, United Kingdom

Submission Status: Open until 6 January 2025

Trending Articles

View which articles have been recently trending


Sign up to receive article alerts

Journal of Inflammation is published continuously online-only and so we encourage you to sign up to receive free email alerts to keep up to date with all of the latest research by registering here.

Resolvins in resolution of Inflammation

Edited by:

Graham Wallace: University of Birmingham, United Kingdom
Submission Status: Open until 30 June 2024

Testing the boundaries of the brain’s immune system

Edited by:
Laura McCulloch:
 University of Edinburgh, UK 
Andrew Greenhalgh: University of Manchester, UK

Submission Status: Open until 1 June 2024

Aims and scope

Journal of Inflammation is an open access, peer-reviewed online journal publishing articles on all aspects of research into inflammation. Non-research articles are specially commissioned by the Editors-in-Chief. 

Read more

Announcing the launch of In Review

Journal of Inflammation, in partnership with Research Square, is now offering In Review. Authors choosing this free optional service will be able to:

  • Share their work with fellow researchers to read, comment on, and cite even before publication
  • Showcase their work to funders and others with a citable DOI while it is still under review
  • Track their manuscript - including seeing when reviewers are invited, and when reports are received 

Submit your review

Journal of Inflammation welcomes review articles on a variety of different topics relating to the scope of the journal. Submit your review today.

For further queries or to discuss the limited funds which may be available to cover the article-processing charge, please contact the editorial team.

Editor-in-Chiefs' profiles

Prof. Paul Kirkham, PhD, FHEA, FRSB, Professor of Cell Biology, University of Wolverhampton, United Kingdom

Professor Kirkham is Professor of Cell Biology at the University of Wolverhampton and a fellow of the HEA. His research interests focus on understanding the mechanisms of disease pathogenesis driven by oxidative stress and its impact on cell function and inflammation, particularly in relation to respiratory disease.

Prof. Adriano Rossi, PhD, DSc, FBS, FBPhS, University of Edinburgh, United Kingdom

Professor Rossi holds the position of Personal Chair in Respiratory and Inflammation Pharmacology at the University of Edinburgh. He is a Fellow of the Society of Biology and a Fellow of the British Pharmacological Society. His research involves investigating the cellular processes and signalling mechanisms controlling inflammation with a focus on understanding inflammation resolution.

New Content Item

Affiliated with the British Inflammation Research Association (BIRAs).

Annual Journal Metrics

  • 2022 Citation Impact
    5.1 - 2-year Impact Factor
    5.1 - 5-year Impact Factor
    1.199 - SNIP (Source Normalized Impact per Paper)
    1.259 - SJR (SCImago Journal Rank)

    2023 Speed
    20 days submission to first editorial decision for all manuscripts (Median)
    113 days submission to accept (Median)

    2023 Usage 
    675 Altmetric mentions